SM
ATXS

Sabby Management’s Astria Therapeutics ATXS Stock Holding History

Sabby Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-46
Closed -$171K – 111
2020
Q3 		$171K Buy
46
+29
+171% +$1.15K 0.03% 103
2020
Q2 		$65K Buy
+17
New +$605 0.01% 88

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sabby Management's ATXS Position: Q1 2021 in Review

Sabby Management sold out of Astria Therapeutics (ATXS) in Q1 2021, closing a stake of 18,004 shares — an estimated $231K sold.

Sabby Management first reported a position in ATXS in Q4 2020 and held it in 1 quarter. The position peaked at $231K in Q4 2020. 61 funds tracked by Wall St. Rank hold ATXS as of Q1 2021.

  • Sabby Management reported no remaining Astria Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Sabby Management sold 18,004 Astria Therapeutics shares in Q1 2021, an estimated $231K.
  • Sabby Management first reported a position in Astria Therapeutics in Q4 2020 and held it in 1 quarter.
  • Sabby Management's Astria Therapeutics position peaked at $231K in Q4 2020.
  • 61 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.